通过全基因组筛选鉴定细胞周期靶向 microRNAs。

Identification of cell cycle-targeting microRNAs through genome-wide screens.

机构信息

a Department of Cancer Biology, Dana-Farber Cancer Institute, and Department of Genetics , Harvard Medical School , Boston , MA , USA.

b Department of Oncology-Pathology , Karolinska Institutet , Stockholm , Sweden.

出版信息

Cell Cycle. 2017;16(23):2241-2248. doi: 10.1080/15384101.2017.1380132. Epub 2017 Nov 14.

DOI:10.1080/15384101.2017.1380132

PMID:29099267

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5788471/

Abstract

By performing nine genome-wide microRNA (miRNA) screens, we recently uncovered a new class of miRNAs, which target multiple cyclins and cyclin-dependent kinases (CDKs). Systemic delivery of selected cell cycle-targeting miRNAs to mouse xenograft models resulted in potent anti-tumorigenic effects without affecting animals' health. Here, we provide an in-depth description of our miRNA screening methodology, analyses of selected cell cycle-targeting miRNAs, and discuss why miRNA therapy might be a viable therapeutic option for cancer patients.

摘要

通过进行九项全基因组 microRNA（miRNA）筛选，我们最近发现了一类新的 miRNAs，它们靶向多个细胞周期蛋白和细胞周期蛋白依赖性激酶（CDKs）。将选定的靶向细胞周期的 miRNA 系统递送至小鼠异种移植模型中，可产生强大的抗肿瘤作用，而不会影响动物的健康。在这里，我们提供了我们 miRNA 筛选方法的详细描述，对选定的靶向细胞周期的 miRNAs 的分析，并讨论了 miRNA 治疗为何可能成为癌症患者的可行治疗选择。